A Phase 2a Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

Start Date01 Mar 2025

Sponsor / Collaborator

Clear Scientific, Inc.

[+1]

NCT05971043 / Not yet recruitingNot ApplicableIIT

Skin Disorders in Patients Using Methamphetamine

1. To detect the skin diseases in patients using methamphetamine

Start Date03 Aug 2023

Sponsor / Collaborator

Assiut University

IRCT20120502009620N2 / RecruitingNot ApplicableIIT

Comparing the Effect of Transcranial Direct Current Stimulation (tDCS) With Cognitive-Behavioral therapy (CBT) Interventions on the stress and anxiety and depression and relapse in abstinent methamphetamine-dependent subjects in Farabi Hospital.

Start Date23 Jul 2022

Sponsor / Collaborator

Kermanshah University of Medical Sciences

100 Clinical Results associated with Methamphetamine Hydrochloride

100 Translational Medicine associated with Methamphetamine Hydrochloride

100 Patents (Medical) associated with Methamphetamine Hydrochloride

109

Literatures (Medical) associated with Methamphetamine Hydrochloride

01 Jan 2025·DRUG AND ALCOHOL DEPENDENCE

Effects of the kappa-opioid receptor antagonist nor-binaltorphimine on methamphetamine-vs-food choice in male rhesus monkeys

Article

Author: Rice, Kenner C ; Banks, Matthew L

BACKGROUND:

Kappa-opioid receptors (KOR) are hypothesized to be involved in mediating ongoing methamphetamine self-administration. Previous rat studies have demonstrated that treatment with the KOR antagonist nor-binaltorphimine (nor-BNI) decreases methamphetamine self-administration. However, KOR antagonist effects on methamphetamine self-administration in nonhuman primates are unknown.

METHODS:

Operant behavior was maintained under a concurrent schedule of banana-flavored pellets (fixed-ratio 100 schedule) and intravenous methamphetamine injections (0-0.32mg/kg/injection, fixed-ratio 10 schedule) in male rhesus monkeys (n=3). Methamphetamine choice dose-effect functions were determined 7 days before and for up to 28 days following 10mg/kg, intramuscular nor-BNI treatment.

RESULTS:

Under continuous saline treatment conditions, methamphetamine-maintained a dose-dependent increase in choice over the alternative food reinforcer. 10mg/kg nor-BNI failed to attenuate methamphetamine choice and trended towards increased methamphetamine choice. Methamphetamine choice returned to pre-nor-BNI treatment levels by 21 or 28 days in all 3 monkeys.

CONCLUSIONS:

The present results do not support the hypothesis that the KOR/dynorphin system robustly modulates methamphetamine self-administration and that KOR antagonists should be considered as methamphetamine use disorder pharmacotherapies. In contrast, these results suggest KOR antagonism may increase methamphetamine reinforcement through blockade of methamphetamine-induced dynorphin release and consequent feedback inhibition.

01 Jan 2025·EXPERIMENTAL BRAIN RESEARCH

Theta and gamma modulation in the nucleus accumbens as drivers of neurophysiological responses to acute methamphetamine sensitization in mice

Article

Author: Cheaha, Dania ; Samerphob, Nifareeda ; Kumarnsit, Ekkasit ; Wongveerakul, Pongpanot

Methamphetamine (METH) has well-documented long-term effects on the brain, including increased psychomotor activity and behavioral sensitization. However, its immediate effects on the brain's reward system following acute exposure, which may contribute to the development of addiction, are less understood. This study aimed to investigate the effects of acute METH on brain oscillations in the nucleus accumbens of C57BL/6 mice. Mice in the METH group received 5 mg/kg of METH for 5 days during the conditioning phase, followed by an 8-day abstinence period. Afterward, they underwent a 6-minute tail suspension test and were given a 1 mg/kg METH challenge. Local field potential (LFP) data were analyzed for percent total power, mean frequency indices, and phase-amplitude coupling (PAC) to assess the neural effects of METH exposure across these phases. A reduction in theta power was observed across the conditioning, abstinence, and challenge phases of METH exposure. The subsequent METH challenge enhanced gamma oscillations, and PAC analysis revealed a consistent theta-gamma coupling index during both the METH administration and challenge phases. It highlights the sensitivity of the reward system to intense, short-term drug exposure, providing new insights into how acute neural stimulation may contribute to the development of addictive behaviors, reinforcing the brain's vulnerability to drug-induced changes in neural circuitry.

01 Dec 2024·HERZ

Methamphetamine-induced cardiotoxicity: in search of protective transcriptional mechanisms

Review

Author: Meyer, Thomas ; Annawald, Kristin ; Streckfuss-Bömeke, Katrin

Abstract:

Crystalline methamphetamine hydrochloride is an illegal drug with a high addictive potential, better known by its colloquial name “ice” or “crystal meth”. The abuse of this drug has led to significant health problems worldwide. Like other amphetamine-type stimulants, chronic consumption of methamphetamine leads to direct toxic effects on the central nervous system, causing cognitive impairment, depressive behavior, and other severe neurological or psychiatric symptoms. Besides its neurotoxicity, the drug exhibits numerous deleterious effects on the cardiovascular system, including hypertension, accelerated atherosclerosis, vasospasm-induced acute coronary syndromes, sudden cardiac death, and dilated cardiomyopathy with congestive heart failure and left ventricular dysfunction. The excessive release of catecholamines upon methamphetamine exposure causes vasoconstriction and vasospasm, which ultimately lead to hypertension, tachycardia, endothelial dysfunction, and cardiotoxicity. While numerous studies have focused on transcription factors expressed in the brain that cause the neurotoxic effects of the drug, much less is known about transcription factors involved in the development of methamphetamine-induced heart failure. In this article, we provide an overview of the Janus kinase–signal transducer and activator of transcription 3 (JAK–STAT3) pathway involved in ischemia/reperfusion injury in the myocardium, which may be activated by the vasospasm-inducing action of the drug. However, much more work is needed to decipher the precise role of STAT protein family members, including the potentially cardioprotective STAT3, in the pathogenesis of methamphetamine-induced cardiotoxicity.

News (Medical) associated with Methamphetamine Hydrochloride

26 Nov 2024

·www.globenewswire.com

Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results

Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of method comparison study in 510(k) submission NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its method comparison study (the “Method Study”) on its Intelligent Fingerprinting Drug Screening System (the “System”). The Method Study confirmed the sensitivity, specificity, accuracy, and usability of the System, validating its potential for use in workplace drug testing and other applications. This milestone follows INBS’ recently announced strong initial results from its Pharmacokinetic (PK) study, both of which are key achievements on the path to the Company’s FDA 510(k) submission. The Method Study was conducted in collaboration with CenExel, a nationwide clinical research site network. It adhered to clinical research standards, including Good Clinical Practice (GCP) guidelines. The Method Study's primary objective was to compare the results of fingerprint sweat opiate screening tests with those obtained using a validated, traceable liquid chromatography-mass spectrometry (LC-MS/MS) method in a laboratory. With a diverse group of 135 healthy donors and nine system operators, the Method Study demonstrated 82.2% sensitivity, 100% specificity, and 94.1% accuracy for the Intelligent Fingerprinting Drug Screening System. Operators found the System easy to use, with no usage errors generated during the course of the study. “The results of our Method Study reaffirm the accuracy and reliability of our fingerprint-based drug screening system,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “By establishing alignment with laboratory-confirmed results through rigorous testing, we have solidified our drug screening system’s credibility for use in safety-critical industries and beyond. This accomplishment is a significant step on our journey toward transforming drug testing with non-invasive technology.” The Method Study evaluated the System’s three core components: the Drug Screening Cartridge, the Drug Screening Reader and the Fingerprint Collection Kit for laboratory analysis. Subjects were randomized and administered codeine doses, then provided fingerprint sweat specimens to assess the System's ability to detect and quantify drug use accurately. The Method Study’s outcomes highlight the System’s reliability, reinforcing its suitability for pre-employment and workplace drug testing applications. If FDA 510(k) clearance were obtained, INBS believes that this would pave the way for the Company to introduce its innovative fingerprint sweat-based drug screening technology to the US market in 2025. As part of the Company's 510(k) submission, which is expected in the fourth calendar quarter of this year, INBS will include data from its recently concluded PK study alongside the results of its Method Study. The Company's clinical study achievements show the accuracy, reliability, and usability of its technology and reinforce the Company's readiness to address the growing demand for drug testing in the US across safety-critical industries such as construction, mining, and transportation, as well as in the law enforcement, drug rehabilitation, and forensic sectors. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:Intelligent Bio Solutions Inc.info@ibs.incLinkedIn | Twitter Investor & Media Contact:Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa.com

Clinical Result

24 Oct 2023

·www.globenewswire.com

Intelligent Bio Solutions’ Innovative Drug Screening Technology Now Offered in New Zealand

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its expansion into the New Zealand market, representing a significant milestone in the Company’s growth strategy for its Intelligent Fingerprinting Drug Screening System. Drug-related harm in New Zealand equates to a staggering $1.9 billion each year1, with significant societal consequences across communities, workplaces and more. New Zealand employers have a responsibility under the Health and Safety in Employment Act 1992 (HSE Act) to ensure the provision of a safe workplace and take all reasonable measures to safeguard employees while at work2. The HSE Act further requires significant hazards to employees, such as the behaviour of an employee affected by alcohol or drugs, to be eliminated, isolated and minimized3. The Company’s Intelligent Fingerprinting Drug Screening System, which uses fingertip sweat to screen for common drugs of abuse, helps employers to fulfil these legal obligations by offering an efficient, dignified, and non-invasive alternative to traditional and more intrusive point-of-care drug testing methods. Harry Simeonidis, President and CEO of Intelligent Bio Solutions, said, “We are delighted to announce our expansion into New Zealand and observe another key growth milestone. Our primary focus is to meet the screening needs and support the health and safety initiatives of businesses across New Zealand and around the world. Drawing on our success in Australia over the past six months, we aim to continue this progress in New Zealand and other markets by offering an alternative and innovative solution that places a strong emphasis on operational efficiency, fitness for duty, and employee privacy and dignity.” The Company’s Intelligent Fingerprinting Drug Screening System is currently available throughout Australia, the United Kingdom, South America, and parts of Europe and Asia, including Spain and Nepal. In addition to these locations, the Company’s growth plan includes further expansion throughout Asia Pacific, the United States and Canada. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (the “Company”) (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. This hygienic, and cost-effective system is designed to screen for recent use of drugs commonly found in the workplace, including opioids, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: www.ibs.inc Forward-Looking Statements: Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:Intelligent Bio Solutions Inc.info@ibs.inc Investor Contact:Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa.com Media Contact:Cheryl BillsonComma Communicationscheryl.billson@commacomms.com 1 https://www.drugfoundation.org.nz/policy-and-advocacy/drugs-in-nz-an-overview/ 2 https://www.supportadventure.co.nz/assets/Uploads/ACC-alcohol-and-drugs-in-the-workplace.pdf 3 https://www.legislation.govt.nz/act/public/1992/0096/latest/DLM278829.html

31 Mar 2023

·www.drugs.com

ADHD Med Prescriptions Spiked Early in Pandemic

FRIDAY, March 31, 2023 -- Prescriptions for attention deficit hyperactivity disorder (ADHD) medications spiked during the COVID-19 pandemic, a new government report shows. The trend may reflect both greater awareness among adults of ADHD symptoms and increased stress driving people to get the care they need. “This report shows there is this growing population of adults who have been diagnosed with ADHD, and there is need for support for this population,” lead study author Melissa Danielson , a statistician with the U.S. Centers for Disease Control and Prevention, told NBC News . Prescriptions for ADHD have been increasing since 2016, according to the CDC researchers, who used insurance data on prescription medication for that year through 2021 in people ages 5 to 64. The study, published March 31 in the CDC publication Morbidity and Mortality Weekly Report, noted that prescriptions filled for stimulant medication increased to 4.1% in 2021 from 3.6% in 2016 among those enrolled in employer-sponsored insurance. The increase was even more pronounced in certain age groups: Among adolescent and adult females ages 15 to 44 and males ages 25 to 44, prescriptions grew 10% from 2020 to 2021. They also rose nearly 20% among females in an even narrower age range, 20 to 24. The medications tracked in the analysis were stimulants sold under the brands Dexedrine and Adderall, methamphetamine under the brand Desoxyn , and methylphenidate , known as Ritalin . A few factors may play into the increases, including greater awareness about symptoms, particularly symptom differences in women; an increase in all mental health diagnoses during the pandemic, and increased access because of changes in how ADHD is diagnosed, NBC News reported. Telehealth may also have played a role. “People tend to seek out diagnoses during times of stress and crisis, and we have anecdotal evidence that there was a significant increase in people seeking diagnoses during the pandemic,” Joshua Langberg , an ADHD specialist and director of the Center for Youth Social Emotional Wellness at Rutgers University in New Jersey, told NBC News. The changes in how ADHD is diagnosed were due to a 2013 update in guidelines in the Diagnostic and Statistical Manual of Mental Disorders. Among the changes included are ADHD symptoms starting later, at age 12 rather than at age 7, to be eligible for a diagnosis, NBC News reported. Adults also need to have fewer symptoms to qualify. Generally, symptoms of ADHD are inattention, hyperactivity-impulsivity, not following through on instructions, not paying close attention to details, losing things and talking excessively. Mental health providers also saw patients via telehealth during the pandemic and prescribed stimulants without seeing patients in person, NBC News reported. “That increased access allowed some people who had flown under the radar, or who said they were doing well enough, to get help,” J. Russell Ramsay , director of the Adult ADHD Treatment and Research Program at the University of Pennsylvania’s Perelman School of Medicine, told NBC News . Ramsay said there has been both over- and underdiagnosis of the disorder. “A comprehensive evaluation for ADHD is time-consuming, can be costly and it involves not just assessing for ADHD, but other things that can lead to concentration issues such as anxiety, depression and lack of sleep,” he explained. Providers sometimes have limited resources to take this into account, and some telehealth companies and pharmacies are being investigated for potentially overprescribing ADHD medication, NBC News reported. “Because ADHD occurs with other mental health disorders half the time, you have to make sure one of those is not causing symptoms of ADHD,” Dr. Lenard Adler , director of the Adult ADHD Program at NYU Langone, told NBC News . “You have to take a careful history.” Sources Morbidity and Mortality Weekly Report , March 31, 2023 NBC News Posted March 2023 Further Support and Information on COVID-19 COVID-19: Prevention & Investigational Treatments COVID-19 Support Group Coronavirus Disease Guide

100 Deals associated with Methamphetamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Methamphetamine Hydrochloride	N06BA03	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Attention Deficit Disorder With Hyperactivity	US	AJENAT PHARMACEUTICALS LLC	31 Dec 1943
Depressive Disorder	JP	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941
Narcolepsy	JP	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941
Schizophrenia	JP	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2020	Not Applicable	HIV Infections	645	No methamphetamine use	dbdijojrly(rosqhqiqsl): P-Value = 1.84	-	01 Jan 2020
				1-19 days of methamphetamine use
Hawaii Aging with HIV Cardiovascular Study (IAS2019)	Not Applicable	HIV Infections	43	never-used	mtmgyedhfp(ippxihcrkz) = vyuqycxxbu srcyxfgyjx (hylmwczouv )	-	01 Jan 2019
				recent-users	mtmgyedhfp(ippxihcrkz) = qxzmzkvlvh srcyxfgyjx (hylmwczouv )
SFN2018	Not Applicable	Methamphetamine dependence	-	Methamphetamine 0.3 mg/kg	cixjxryxyx(ovtbavbbzs) = wsyasrwfmj namrvtmxnt (ynpknudbqf )	-	03 Nov 2018
				Methamphetamine 2.0 mg/kg	cixjxryxyx(ovtbavbbzs) = nagpmzcvnf namrvtmxnt (ynpknudbqf )
NIDA P30DA011041 (IAS2017)	Not Applicable	-	603	PWID using methamphetamine (Ice)	usnyyrcmft(apivlksjwv) = uisqzwcuaa kpuhaxpwao (ijkeftyoer ) View more	-	01 Jan 2017
SFN2016	Not Applicable	Methamphetamine dependence	-	methamphetamine (Adolescent rats)	lsuhjcrgny(kvyafhtoqe) = goibvmheza bbhqcksihs (qjlrnyfvqq ) View more	-	16 Nov 2016
				methamphetamine (Adult rats)	lsuhjcrgny(kvyafhtoqe) = emoptauysl bbhqcksihs (qjlrnyfvqq ) View more
SFN2015	Not Applicable	Methamphetamine abuse	-	Methamphetamine 20 µM	ctzywpdcua(otrrjprfgd) = Meth decreased K2P channel activity dvvnpdccif (riylimjdrn )	-	19 Oct 2015
				Methamphetamine 100 µM
SFN2015	Not Applicable	Methamphetamine dependence	-	Methamphetamine 1.0 mg/kg	fpvihbphaj(mxrsywdaro) = dehmjzfnmq evqwvyqdwf (bgosyzlsyy )	-	19 Oct 2015
				Methamphetamine 2.0 mg/kg	heweoacaxx(qqpoiskofz) = kyymroofgm xinuxarbfa (nezbkpxfdp )
SFN2014	Not Applicable	-	-	Acute systemic METH	tcsmfugzub(svjddtchuu) = METH evoked minor effects on blood pressure cloerlmxzx (brhrswnljt )	-	19 Nov 2014
				Acute ICV METH
ISC2013	Not Applicable	Cerebral Hemorrhage methamphetamine abuse	384	Methamphetamine (Native Hawaiians and other Pacific Islanders)	wtbdbdvbbx(jckxizihuw) = dddctdrdjr ktgfcajguk (oouiinmxrj ) View more	-	01 Feb 2013
				Methamphetamine (Non-Hispanic whites)	wtbdbdvbbx(jckxizihuw) = osraikcfnh ktgfcajguk (oouiinmxrj ) View more
SFN2011	Not Applicable	-	-	Methamphetamine	mtvicgcywg(tksvndtxub): F = 12.19	-	15 Nov 2011
				D1R antagonist SCH23390

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis